http://www.craneware.com/

Craneware, Inc. is a leading supplier of business intelligence and revenue cycle software that provides clients with chargemaster management software and products designed to optimize legitimate reimbursements and assist in managing the revenue cycle through better information, workflow, pricing strategy, capture of lost revenue and best practice modeling. Our innovative and scalable products are designed to ensure that you have the information you need to succeed in healthcare financial management.

A talented mix of employees from the healthcare industry, software engineering, business consulting, customer support and training provide the perfect blend for providing extremely powerful solutions to problems faced by hospital's financial teams.

Our consultant's years of experience in the healthcare industry are the vital source of financial, clinical and coding expertise that together with talented software developers combine to make our products so effective.

Our dedicated support team work hard at ensuring our customers always come first and pride themselves on exemplary service throughout the relationship from first install to advanced user training. Installation times are in weeks instead of months, Support responses are in minutes instead of days.

Headquartered in Scotland with offices across the US, Craneware delivers unparalleled solutions to the problems facing healthcare financial managers every day.

Significant Contract Win
RNS
RNS Number : 2611A
Craneware plc
23 March 2017
 
Craneware plc
("Craneware", "the Group" or the "Company")
 
Significant Contract Win
 
23 March 2017 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, is pleased to announce a significant new contract with a large hospital operator in the US.
 
This win, with an existing customer, adds further Value Cycle solutions and related services to a seven year contract originally announced in April 2014.  The contract is expected to deliver a further $3.7m of revenue over this new seven year term as the hospital network rolls out these additional solutions across its facilities and $1.5m of additional revenue as the contract for the currently implemented solutions is extended to run co-terminus to this amendment.
 
In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from this contract will be recognised over future periods, adding to the Group's long term visibility of revenue under contract.
 
Keith Neilson, CEO of Craneware plc, commented, "The strategic importance of Craneware's Value Cycle solutions allow us to add new customers and deepen our relationship with our existing customers as both groups address the challenges resulting from the continued evolution to the new value based re-imbursement environment. The extension of the solution set provided to this customer and increasing the duration of the original contract underlines the value our solutions bring to our customers. We have a very positive relationship with our customers, demonstrating sustainable value; we now look forward to this extension of our working relationship with this customer to over a decade."

26 Apr
Peel Hunt
1,450.00
Buy

08:00 11/07/2017
Broker Forecast - Peel Hunt issues a broker note on Craneware PLC
Peel Hunt today reaffirms its buy investment rating on Craneware PLC (LON:CRW) and raised its price target to 1495p (from 1450p). Story provided by StockMarketWire.com

Final Results
RNS
RNS Number : 7912P
Craneware plc
05 September 2017
 
Craneware plc
("Craneware", "the Group" or the "Company")
Final Results
Double digit revenue and profit growth and successful transition into execution phase of the growth strategy
 
5 September 2017 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its results for the year ended 30 June 2017.
 
Financial Highlights (US dollars)
·      Revenue increased 16% to $57.8m (FY16: $49.8m)
·      Adjusted EBITDA1.  increased 13% to $18.0m (FY16: $15.9m)
·      Profit before tax increased 22% to $16.9m (FY16:  $13.9m)
·      Basic adjusted EPS increased 20% to $0.514 (FY16:  $0.429) and adjusted diluted EPS increased to $0.503 (FY16: $0.423)
·      Total visible revenue increased 13% to $163.8m (FY16 same 3 year period: $145.3m)
·      Continued operating cash conversion above 100% of Adjusted EBITDA
·      Cash at year-end of $53.2m (FY16: $48.8m) after payment of $6.4m dividend to shareholders and increased investment of over $3.0m in R&D
·      Proposed final dividend of 11.3p (14.71 cents) per share giving a total dividend for the year of 20.0p (26.04 cents) per share (FY16: 16.5p (22 cents) per share)
·      Renewal rate remains above 100% by dollar value
 
1.  Adjusted EBITDA refers to earnings before acquisition and share related transaction costs, interest, tax, depreciation, amortisation and share based payments.
 
Operational Highlights
·      Continued supportive market environment as the US healthcare market evolves towards value-based care, with a critical dependency on accurate financial and operating data
·      Continued high levels of customer acquisition and retention
·      Successful launch of cloud-based Trisus™ platform, with extremely positive customer response
·      Initial sales of Trisus Claims Informatics™, the first product on the Trisus™ platform
·      Early adopters secured for Craneware Healthcare Intelligence, the Group's new business focused on healthcare Cost Analytics and Resource Efficiency (CARE)
·      Record sales pipeline for the current financial year
 
Keith Neilson, CEO of Craneware plc commented, "We are delighted to report that, with record levels of revenue and profitability, the launch of our Trisus platform with secured sales for the first Trisus product (Trisus Claims Informatics™), and the launch of Craneware Healthcare Intelligence, this was the year in which we saw our unique vision of the Value Cycle, turn from concept to reality.
 
"While laying out our vision for the Value Cycle over the last two years, Craneware has delivered double digit growth in our key metrics, including revenue and profit, supported by sales success throughout the period. We have expanded our product suite into the Value Cycle; developed a new cloud-based technology platform, Trisus; and created a new Group business, Craneware Healthcare Intelligence, all significantly increasing the Company's total addressable market. At the same time we have been investing in improving our customers' experience and have returned in excess of $15m to shareholders by way of dividends and share buy backs.
 
"The unceasing evolution of the US healthcare market towards value-based care presents us with an ongoing, growing market opportunity and the investments we have made mean we now have the potential to deliver against this expanding opportunity. With our sales pipeline increasing each year, this increased scalability and opportunity, combined with our high levels of revenue visibility, strong cash position and extensive customer base provide us with confidence in Craneware's ongoing success."

5 Sep
Peel Hunt
1,495.00
Buy

Anyone subscribing to the MoneyAM Level 2 platform please take note that most days it is not reporting the correct Trade High nor Trade Low information and "some days" not reporting the correct Opening Price or Closing Price.

The reason is because MoneyAM's Level 2 system is not correctly sensing the Auto Trades or Ordinary Trades correctly so is wrongly reporting them

Craneware shareholders approve 11.3p final divi
StockMarketWire.com
Craneware has confirmed that shareholders approved the proposed final dividend of 11.3p per share at today's Annual General Meeting, taking the total dividend for the year to 20p.

The final dividend will be paid on 7 December to shareholders on the register as at 10 November, with a corresponding ex-Dividend date of 9 November.



At 1:14pm: (LON:CRW) Craneware PLC share price was +10p at 1325p


Story provided by StockMarketWire.com

Significant Contract Win
RNS
RNS Number : 0253V
Craneware plc
31 October 2017
 
Craneware plc
("Craneware", "the Group" or the "Company")
 
Significant Contract Win
 
31 October 2017 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, is pleased to announce the renewal and significant expansion of an existing contract with a growing hospital operator in the US.
 
This $6m win sees the extension of a relationship that has been in place since 2007, with the renewal of the customer's existing Value Cycle solutions and the roll out of these same solutions to further facilities that have been recently acquired by this hospital network.  The contract is expected to deliver $3.5m of incremental revenue over this new five year term as the hospital network rolls out these solutions at its additional facilities.
 
In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from this contract will be recognised over future periods, adding to the Group's long term visibility of revenue under contract.
 
Keith Neilson, CEO of Craneware plc, commented, "The expansion of this relationship demonstrates the strategic importance of Craneware's Value Cycle solutions to our customers, as they extend their own hospital networks throughout the US.   The strength of our solutions and the value they deliver to all customers, including large and complex health systems, allows us to deepen our relationship with our customers as they address the challenges resulting from the continued evolution to the new value based re-imbursement environment.
 
"Having enjoyed our positive working relationship for a decade, we now look forward to continuing to deliver sustainable value throughout this new term."

AGM Statement
RNS
RNS Number : 8493V
Craneware plc
08 November 2017
 
Craneware plc
("Craneware", "the Group" or the "Company")
AGM Statement
 
8 November 2017 - Craneware plc (AIM: CRW.L), the leader in Value Cycle solutions for the US healthcare market, will be holding its Annual General Meeting today at 2pm. At the meeting, Keith Neilson, CEO of the Company, will make the following statement:
 
"We have experienced a positive start to trading in the first four months of the year, adding to the recent announcement of the $6m contract win extending the scope of our solutions within an existing customer. In June, we launched Trisus Claims Informatics, the first product on our cloud-based Trisus platform, to which we have seen a positive market response.  In addition, we are seeing very encouraging results for the early adopters of our Trisus Cost Analytics Resource Efficiency product, which is currently under development within Craneware Healthcare Intelligence.
 
"The sales activity and the early product successes demonstrate how we are benefiting from our ongoing investments in our Value Cycle product suite, ensuring we have the solutions that provide insight into key areas of hospital operations, expanding our market opportunity and increasing our strategic value within our market.
 
"Our leadership in this area has further strengthened Craneware's position as a trusted partner for US healthcare organisations as they look to solve the challenges of the new value based reimbursement models.
 
"This positive impact of the Value Cycle on current sales and underlying pipelines combined with the high levels of revenue visibility and significant cash reserves, means we are well positioned to continue to execute on our growth strategy."
 

Dividend Currency Election
RNS
RNS Number : 2046W
Craneware plc
10 November 2017
 
 
Craneware plc
("Craneware" or the "Company")
 
Dividend Currency Election
 
10 November 2017 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, today gives further information regarding its final dividend announced on 5 September 2017.
 
For those shareholders who have previously registered to receive their dividend in US dollars under the Company's Dividend Currency Election, the dividend will be paid at an exchange rate of $1.31/£1.

3 Jan
Peel Hunt
1,800.00
Buy

Trading Update and Significant Contract Win
RNS
RNS Number : 1640B
Craneware plc
08 January 2018

Craneware plc
("Craneware", "the Group" or the "Company")

Trading Update and Significant Contract Win

8 January 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the six months ended 31 December 2017.

The Group is pleased to announce that it has continued to perform strongly in the first half of the financial year as it executes on its growth strategy. There has been strong underlying sales growth which has been extended by a significant new contract with one of the largest healthcare provider networks (the 'Network') in the US, further details provided below.

Renewals by dollar value have continued at over 100% in the period. In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from both new and renewal sales successes will be recognised over future periods, adding significantly to the Group's long term visibility of revenue under contract.

As a result, the Group expects to report increases in both revenue and adjusted EBITDA in the range of 15% to 18% for the six month period ended 31 December 2017, continuing the double digit growth delivered in the prior year.

The Group maintains healthy cash reserves of over $50m (H117: $45m) and has a further funding facility available from the Bank of Scotland of up to $50m. The Group continues to investigate opportunities to deploy these reserves.

With the growth in contracts signed in the period, continued sales momentum and high levels of revenue visibility, the Board is confident in meeting market expectations for the full year.

Significant Contract Win
This contract is expected to deliver in excess of $16m of revenue over its initial five year term as Craneware's Value Cycle solutions are utilised by over 75 new facilities across the Network. Having previously contracted to utilise Craneware's software in a small number of its hospitals, the customer carried out an assessment of the potential financial and operational impact Craneware's solution could bring to the entire Network. This has resulted in the roll out of Craneware's software across the Network with Craneware hosting the solution as part of the Network's strategic financial performance plans.

Notice of Results
The Company will announce results for the six months ended 31 December 2017 on 6 March 2018.

Keith Neilson, CEO of Craneware plc, commented, "These results, including a contract with one of the largest healthcare providers in the US, demonstrate the ongoing momentum we are experiencing in the business.

"The strength of our solutions and the value they deliver to all strata of customers, including large and complex health systems, allows us to support our customers as they address the challenges resulting from the continued evolution of the US Healthcare market. We are playing an increasingly strategic role in assisting healthcare providers as they look to improve and sustain their financial performance, whilst mitigating operational and compliance risks.

"These factors combined with our financial strength and high levels of visible revenue for future years, gives management confidence in its ongoing ability to deliver increasing stakeholder value this year and in the future."

Share buyback

1 Feb
Peel Hunt
1,800.00
Buy

Significant Contract Wins
RNS
RNS Number : 6550E
Craneware plc
13 February 2018

Craneware plc
("Craneware", "the Group" or the "Company")

Significant Contract Wins

13 February 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, is pleased to announce two significant new contracts with hospital providers in the US. Both hospital providers are new customers to Craneware.

The first contract with a large blue chip healthcare provider, sees Craneware's Value Cycle products being deployed across this organisation's 20 hospitals. Craneware's solutions will be an integral part of this provider's major system change, helping to ensure revenue integrity during the initiative and beyond. This contract is expected to deliver c$5m of revenue over its initial multi-year term.

The second contract win with an innovative surgical hospital is for the provision of Craneware's suite of products as part of its strategic growth plans, deploying multiple Craneware solutions, including the Trisus Platform and Trisus Claims Informatics. This provider is focused on improving all aspects of its value cycle. This multi-year contract is expected to deliver c$3.5m of revenue over its initial term.

In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from these two contracts will be recognised over future periods, adding to the Group's long term visibility of revenue under contract, supporting ongoing financial performance.

Keith Neilson, CEO of Craneware plc, commented, "These contract wins confirm that the positive momentum and financial success we reported in the first half of the year has continued into the second half.

"This is further evidence of the strategic importance and value that Craneware's solutions can bring to all sizes and complexities of hospital healthcare providers, as they look to address the challenges they face with the ongoing evolution of the US Healthcare market.

"This continued momentum across the entire business, combined with the strength of our solution set, means we are well positioned to support our customers in the new era of value-based care and deliver increasing stakeholder value."

Half-year Report
RNS
RNS Number : 7619G
Craneware plc
06 March 2018

Craneware plc
("Craneware", "the Group" or the "Company")

Interim Results

6 March 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its unaudited results for the six months ended 31 December 2017.

Financial Highlights (US dollars)

· Revenue increased 16% to $31.1m (H1 2017: $26.8m)
· Adjusted EBITDA1 increased 18% to $9.7m (H1 2017: $8.2m)
· Profit before tax increased 16% to $8.7m (H1 2017: $7.5m)
· Adjusted basic EPS increased 18% to 25.4 cents per share (H1 2017: 21.6 cents per share)
· Cash position of $52m (H1 2017: $45m) following dividend payment of $4.1m
· Proposed interim dividend increased 15% to 10p (H1 2017: 8.7p per share)

1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments and acquisition and share transaction related costs.

Operational Highlights

· Two significant contracts secured in the half, with a further two announced post period end
· Continued supportive market environment as the US healthcare market evolves towards value-based care, with a critical dependency on accurate financial and operating data
· Continued high levels of customer acquisition and retention
· Increasing market engagement with our newly launched cloud-based platform, Trisus™
· Strong sales and opportunities across the product suite and across all classes of hospital providers, including for the first Trisus product: Trisus Claims Informatics
· Early adopters reporting positive results for our new Cost Analytics and Resource Efficiency software (Trisus CARE), the next Trisus software release

Outlook

· Record sales pipeline for the current financial year
· Total visible revenue of over $63.1m for the current financial year and $179.4m for the three-year period to June 2020 (H1 2017 same three year period: $149.1m)
· Board confident in outlook for the year

Keith Neilson, CEO of Craneware plc commented, "Our extensive expertise and experience in the US healthcare market means we are well positioned to provide actionable insight for our customers. By combining their financial and operational data in unique ways, our solutions ensure they can continue to thrive in the new era of value-based care.

"The investments made into Craneware's product suite and operations in recent years means we are now delivering growth rates which are outperforming our industry. We are seeing growing interest across our enlarged product suite and are particularly pleased with the high levels of interest and opportunities across our customer base for our newly launched cloud-based platform, Trisus.

"With an ongoing, growing market opportunity, a record sales pipeline and increasing long-term revenue visibility, we enter the second half of the year with great confidence for the future and the ongoing success of the business."

08:30 03/05/2018
Broker Forecast - Peel Hunt issues a broker note on Craneware PLC
Peel Hunt today reaffirms its buy investment rating on Craneware PLC (LON:CRW) and set its price target at 2100p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

Trading Update and Significant Contract Win
RNS
RNS Number : 0806U
Craneware plc
10 July 2018

Craneware plc
("Craneware", "the Group" or the "Company")

Trading Update and Significant Contract Win

10 July 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the year ended 30 June 2018.

The Group is pleased to announce continued outstanding performance, as it executes on its growth strategy. There has been strong underlying new sales growth that increased by approximately 100%. This includes a further significant new contract signed at the end of the year. This contract with a large healthcare provider network ('the Network') in the Eastern US is for the Company's Pharmacy ChargeLink® solution. Further details on the contract are provided below.

Renewals by dollar value have continued at over 100% in the period. In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from both new and renewal sales successes will be recognised over future periods, adding significantly to the acceleration of the Group's long term visibility of revenue under contract.

In addition to this record sales performance, the Group expects to report increases of approximately 16% in revenue and 20% in adjusted EBITDA for the year ended 30 June 2018, extending the run of organic double digit growth delivered in prior years.

Having returned $15m to shareholders and invested a further $4m in the Employee Benefit Trust during the year, the Group's cash conversion has resulted in the cash balances returning to similar levels to those seen at the end of FY17 (FY17: $53m).

Further Significant Contract Win
Craneware has signed a significant new contract, with a large hospital network in the Eastern US, for its Pharmacy ChargeLink® solution. From October 2018, Craneware's solution will be rolled out to the 12 facilities across the Network. This contract is expected to deliver in excess of $6m of revenue over its initial five year term. As per the revenue recognition policy all of the revenue from this contract will be recognised in future periods.

Notice of Results
The Company will announce results for the year ended 30 June 2018 on 4 Sept 2018.

Keith Neilson, CEO of Craneware plc, commented, "These record results demonstrate the ongoing momentum we are seeing across all strata of hospitals including large and complex health systems as they embrace the realities of value-based economics within healthcare.

"The strength of our solutions and the value they deliver to our customers, allows us to support our customers as they address the challenges resulting from the continued evolution of the US Healthcare market. We are playing an increasingly strategic role in assisting healthcare providers to deliver better healthcare through sustainable financial performance, whilst mitigating operational and compliance risks.

"These factors combined with our financial strength and high levels of visible revenue for future years, gives management confidence in its continuing ability to deliver increasing stakeholder value year on year whilst investing in our future."

09:20 10/07/2018
Broker Forecast - Peel Hunt issues a broker note on Craneware PLC
Peel Hunt today reaffirms its buy investment rating on Craneware PLC (LON:CRW) and raised its price target to 2500p (from 2100p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

Final Results
RNS
RNS Number : 6425Z
Craneware plc
04 September 2018

Craneware plc
("Craneware", "the Group" or the "Company")

Final Results

4 September 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its audited results for the year ended 30 June 2018.

Financial Highlights (US dollars)
· Revenue increased 16% to $67.1m (FY17: $57.8m)
· Adjusted EBITDA1. increased 20% to $21.6m (FY17: $18.0m)
· Profit before tax increased 12% to $18.9m (FY17: $16.9m)
· Basic adjusted EPS2. increased 17% to $0.602 (FY17: $0.514) and adjusted diluted EPS increased to $0.591 (FY17: $0.503)
· Total visible revenue increased 20% to $192.9m (FY17 same 3 year period: $160.7m)
· Continued operating cash conversion above 100% of Adjusted EBITDA
· Renewal rate remains above 100% by dollar value
· Cash at year-end of $52.8m (FY17: $53.2m) after having returned $23.2m to shareholders via a share buyback and dividends, while also investing $4.2m in the Employee Benefit Trust
· Proposed final dividend of 14.0p (18.48 cents) (FY17: 11.3p, 14.71 cents) per share giving a total dividend for the year of 24.0p (36.68 cents) (FY17: 20.0p, 26.04 cents) per share

1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation and share based payments.
2. Adjusted Earnings per share calculations allow for the tax adjusted acquisition costs and share related transactions together with amortisation on acquired intangible assets.

Operational Highlights

· Over 100% increase in new sales in the year, including five significant contracts wins or contract extensions
· Continued supportive market environment as the US healthcare market evolves towards value-based care, with a critical dependency on accurate financial and operating data
· Continued high levels of customer acquisition and retention
· Increasing market engagement with newly launched cloud-based platform, Trisus™
· Strong sales and opportunities across the product suite and across all classes of hospital providers, including for the first Trisus product: Trisus Claims Informatics
· Early adopters reporting positive results for our new Craneware Healthcare Intelligence software, the next Trisus software release

Outlook

· Record sales pipeline for the current financial year
· Board confident in outlook for the year and beyond

Keith Neilson, CEO of Craneware plc commented, "While the past year has been outstanding in terms of financial results and operational progress, this is by no means the end of the journey and we are excited by the far greater opportunity that lies ahead. It is clear that the investments we have made into the organisation's design, people and products are delivering excellent results, and we will continue to invest in our people and business to ensure we have the capabilities to succeed. We believe that the breadth of our customer base and the quantity of data within our solutions means we have the opportunity to sit at the heart of the move to value-based economics; collating and analysing the information that will support hospital-wide decision making and ultimately have a positive impact on the quality of healthcare.

"With an ongoing, growing market opportunity, a record sales pipeline and increasing long-term revenue visibility, we enter the new financial year with great confidence for the future and the ongoing success of the business."